EQRx Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

EQRx şirketinin toplam hissedar öz sermayesi $1.2B ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $1.2B ve $69.4M dir.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	n/a
Nakit	US$1.21b
Eşitlik	US$1.17b
Toplam yükümlülükler	US$69.37m
Toplam varlıklar	US$1.24b

Son finansal sağlık güncellemeleri

Recent updates

We're Hopeful That EQRx (NASDAQ:EQRX) Will Use Its Cash Wisely

Jul 25

EQRx (NASDAQ:EQRX) Is In A Good Position To Deliver On Growth Plans

Feb 22

We're Not Very Worried About EQRx's (NASDAQ:EQRX) Cash Burn Rate

Nov 08

EQRx: Saving American Lives, Made Possible By Low Cost Chinese Drugs

Aug 28

 EQRx GAAP EPS of -$0.17 beats by $0.03

Aug 11

Here's Why We're Not Too Worried About EQRx's (NASDAQ:EQRX) Cash Burn Situation

Jul 24

We Think EQRx (NASDAQ:EQRX) Can Afford To Drive Business Growth

Apr 08

EQRx (NASDAQ:EQRX) Is In A Good Position To Deliver On Growth Plans

Dec 24

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: EQRX 'nin kısa vadeli varlıkları ( $1.2B ) kısa vadeli yükümlülüklerini ( $65.8M ) aşıyor.

Uzun Vadeli Yükümlülükler: EQRX şirketinin kısa vadeli varlıkları ( $1.2B ) uzun vadeli yükümlülüklerini ( $3.6M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: EQRX borçsuzdur.

Borcun Azaltılması: EQRX un 5 yıl önce borcu yoktu.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: EQRX şirketinin mevcut serbest nakit akışına göre 3 yıldan fazla bir süre için yeterli nakit pistine sahip olduğu belirtiliyor.

Tahmini Nakit Akışı: EQRX, serbest nakit akışı her yıl % 23.9 oranında tarihi oranda azalmaya devam ederse 3 yıldan fazla bir süre yeterli nakit akışına sahip olur

EQRx Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

EQRx, Inc. Files Form 15

We're Hopeful That EQRx (NASDAQ:EQRX) Will Use Its Cash Wisely

EQRx (NASDAQ:EQRX) Is In A Good Position To Deliver On Growth Plans

We're Not Very Worried About EQRx's (NASDAQ:EQRX) Cash Burn Rate

Here's Why We're Not Too Worried About EQRx's (NASDAQ:EQRX) Cash Burn Situation

We Think EQRx (NASDAQ:EQRX) Can Afford To Drive Business Growth

Recent updates

EQRx, Inc. Files Form 15

EQRx, Inc.(NasdaqGM:EQRX) dropped from NASDAQ Composite Index

Revolution Medicines, Inc. (NasdaqGS:RVMD) completed the acquisition of EQRx, Inc. (NasdaqGM:EQRX) from a group of shareholders.

EQRx, Inc.(NasdaqGM:EQRX) dropped from S&P Global BMI Index

Revolution Medicines, Inc. (NasdaqGS:RVMD) entered into a definitive agreement to acquire EQRx, Inc. (NasdaqGM:EQRX) from a group of shareholders.

New minor risk - Share price stability

We're Hopeful That EQRx (NASDAQ:EQRX) Will Use Its Cash Wisely

EQRx (NASDAQ:EQRX) Is In A Good Position To Deliver On Growth Plans

EQRx, Inc. Announces Acceptance of Marketing Authorization Application by the Uk's Medicines and Healthcare Products Regulatory Agency for Sugemalimab in Metastatic Non-Small Cell Lung Cancer

EQRx, Inc. Announces Acceptance of Marketing Authorization Application by the European Medicines Agency for Aumolertinib in EGFR-Mutated Non-small Cell Lung Cancer

High number of new and inexperienced directors

We're Not Very Worried About EQRx's (NASDAQ:EQRX) Cash Burn Rate

EQRx: Saving American Lives, Made Possible By Low Cost Chinese Drugs

&nbsp;EQRx GAAP EPS of -$0.17 beats by $0.03

EQRx Announces Late-Breaking Oral Presentation of Final Progression-Free Survival Results from Phase 3 Trial of Sugemalimab in Stage III Non-small Cell Lung Cancer at IASLC 2022 World Conference on Lung Cancer

Here's Why We're Not Too Worried About EQRx's (NASDAQ:EQRX) Cash Burn Situation

EQRx, Inc., Annual General Meeting, Sep 30, 2022

Eqrx Announces Acceptance of Marketing Authorization Application by U.K.'s Medicines and Healthcare Products Regulatory Agency for Aumolertinib

EQRx, Inc. Announces New Data for Lead Oncology Programs in Non-Small Cell Lung Cancer

High number of new and inexperienced directors

We Think EQRx (NASDAQ:EQRX) Can Afford To Drive Business Growth

EQRx, Inc. and CStone Pharmaceuticals Announce Sugemalimab Demonstrates Statistically Significant Overall Survival Benefit in Patients with Stage IV Non-Small Cell Lung Cancer

High number of new and inexperienced directors

EQRx (NASDAQ:EQRX) Is In A Good Position To Deliver On Growth Plans

No independent directors

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin

EQRx GAAP EPS of -$0.17 beats by $0.03